Cipla expands partnership with Roche Pharma India to further improve access to key oncology medicines Kumar Jeetendra | June 18, 2020 Mumbai 18th June 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) and Roche Products (India) Pvt. Ltd. (Roche Pharma) today announced that the two companies have entered into an agreement to provide better access to innovative medicines for patients in India. Under this agreement, Cipla will be responsible for …
Jubilant Therapeutics reports preclinical information of double LSD1 and HDAC6 at AACR 2020 Kumar Jeetendra | June 23, 2020 Jubilant Therapeutics Inc., a biopharmaceutical organization propelling little particle modulators to address neglected clinical needs in oncology and immune system infections, today declared that preclinical information of double LSD1 and HDAC6 inhibitor JBI-802, will be introduced in a banner meeting at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The preclinical …
MD Anderson and Sanofi work together to quicken improvement of imaginative malignant growth treatments Kumar Jeetendra | July 15, 2020 At the University of Texas MD Anderson Cancer Center and Sanofi currently declared a last-minute tactical alliance to hasten the evolution of investigational treatments, for example immune and targeted treatments, for patients with cancer. “Our goal is to enhance the results for patients using a selection of difficult-to-treat cancers, that will be best achieved via …
Harbour BioMed and Viva Biotech declare key coordinated effort to promote biotech new startups Kumar Jeetendra | August 1, 2020 HBM will combine its top Harbour Mice® stage H2L2 and its expertise in global research and development of innovative molecules, with Viva Biotech’s structure-based early phase drug discovery services. This complementary partnership will provide advanced biotech startups access to next generation technologies that create synergies to accelerate the route between ideation to merchandise. The incubated …
Novel medication could improve future and quality for patients with difficult to-treat malignant growths Kumar Jeetendra | September 9, 2020 The Sheffield researchers founded the spin-out Modulus Oncology with a group of experienced biotech entrepreneurs to fast-track the drug into clinical testing over two decades. The researchers founded the spin-out firm Modulus Oncology, along with a team of seasoned biotech entrepreneurs, to fast-track the drug into clinical testing over two years. The Sheffield team made …
New initiative identifies key parameters Inherent effective anti-tumor immunity Kumar Jeetendra | October 10, 2020 Neoantigens, tiny markers that arise from cancer mutations, flag cells as cancerous and could be the key to unlocking a new generation of immunotherapies. Targeting the”right” neoantigens – at a cancer vaccine or a cell treatment – has the promise to eliminate a patient’s cancer with minimal side effects. But countless mutations can exist in …
Drug used to control pulse may improve malignant growth patients’ reaction to immunotherapy Kumar Jeetendra | November 1, 2020 The exact same biochemical triggers which spur a”flight or fight” reaction once we encounter threats may help tumor cells to thrive. A group of researchers from Roswell Park Comprehensive Cancer Center is looking at ways to interrupt that dynamic so that cancer therapies can be effective. Their latest work, published today in Clinical Cancer Research, …
Blood vessel deformities start in vein cells Kumar Jeetendra | November 3, 2020 In the condition called cavernoma, lesions appear in a cluster of blood vessels in the brain, spinal cord or retina. Researchers from Uppsala University can now reveal, at molecular level, these changes originate in vein cells. This new understanding of the condition creates possibility of developing better treatments for patients. The study was published in …
BioMed X Institute Announces Expansion of their Strategic Collaboration with Janssen in Immunology Research Kumar Jeetendra | November 9, 2020 HEIDELBERG, Germany, November 09, 2020 / B3C newswire / — German independent research institute BioMed X adds a further research program in the field of immunology to their existing collaboration with Janssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson: The new project will focus on the development of …
Dexamethasone use could reduce immune checkpoint inhibitor viability in glioblastoma patients Kumar Jeetendra | November 25, 2020 Bottom Line: One of patients with glioblastoma getting an immune checkpoint inhibitor, people who obtained the corticosteroid dexamethasone at baseline for cerebral edema had significantly worse overall survival. Journal Where the Study was Released: Clinical Cancer Research, a journal of the American Association for Cancer Research Author: David A. Reardon, MD, clinical director of the …
New comprehension of physical properties of chromatin may show how genome is encoded and decoded Kumar Jeetendra | December 21, 2020 University of Alberta researchers have found an answer to a basic question in genomic biology that has eluded scientists because the discovery of DNA: Over the nucleus of our cells, is the complex package of DNA and proteins called chromatin a solid or a liquid? Previously, fields like biochemistry operated under the premise that chromatin …
Surgery may expand length of endurance for metastatic breast malignant growth patients Kumar Jeetendra | December 28, 2020 They studied nearly 13,000 stage four breast cancer patients and found that those who had surgery as well as their other remedies had a survival advantage over those who had other therapies alone. Stage four breast cancer accounts for 6% of newly-diagnosed breast cancer cases. Systemic treatment, which may include treatments like chemotherapy, hormone therapies …
